Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) said preliminary, unaudited net product revenue for its lead narcolepsy drug WAKIX reached approximately $868 million in 2025, setting the …
Harmony’s WAKIX Surges Toward Blockbuster Status as Revenue Nears $1 Billion Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported new late-stage clinical data showing its experimental epilepsy drug EPX-100 delivered sharp and sustained seizure reductions in patients with …
Harmony’s Epilepsy Drug Cuts Seizures in Half in Key Late-Stage Study Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently reported encouraging data from its pivotal bioequivalence study for pitolisant gastro-resistant (GR), marking a major milestone as the company …
Harmony’s Next-Gen Narcolepsy Drug Advances With Surprising New Results Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has begun dosing participants in a Phase 1 clinical study of BP1.15205, a next-generation orexin 2 receptor agonist positioned as …
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will showcase its strategy and pipeline to the investment community next week, with executives slated to appear at three major …
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences Read More PLYMOUTH MEETING, PA — Harmony Biosciences posted another quarter of rapid expansion, driven by accelerating demand for its flagship narcolepsy therapy WAKIX® and a late-stage pipeline approaching multiple Phase 3 …
Harmony Biosciences Surges on Strong WAKIX Growth as Cash Position Climbs to $778M Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported topline results from its Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome (FXS), announcing that the trial …
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New …
Harmony Biosciences to Present at Cantor Global Healthcare Conference Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) reported another quarter of double-digit revenue growth and solidified its position as a profitable, late-stage biotech leader, driven by continued momentum …
Harmony Biosciences Delivers Strong Q2 Growth, Advances Late-Stage Pipeline Read More PLYMOUTH MEETING, PA — Harmony Biosciences recently revealed compelling preclinical data for BP1.15205, a highly potent and selective orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of the …
Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment Read More